259 related articles for article (PubMed ID: 32653622)
1. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
Chhabra S; Visotcky A; Pasquini MC; Zhu F; Tang X; Zhang MJ; Thompson R; Abedin S; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Douglas Rizzo J; Runaas L; Saber W; Shah NN; Shaw BE; Horowitz MM; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1876-1885. PubMed ID: 32653622
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
3. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Kanate AS; Hari PN; Pasquini MC; Visotcky A; Ahn KW; Boyd J; Guru Murthy GS; Rizzo JD; Saber W; Drobyski W; Michaelis L; Atallah E; Carlson KS; D'Souza A; Fenske TS; Cumpston A; Bunner P; Craig M; Horowitz MM; Hamadani M
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1295-1302. PubMed ID: 28412518
[TBL] [Abstract][Full Text] [Related]
4. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
Rodriguez N; Lee J; Flynn L; Murray F; Devlin SM; Soto C; Cho C; Dahi P; Giralt S; Perales MA; Sauter C; Ponce DM
Transplant Cell Ther; 2021 Nov; 27(11):920.e1-920.e9. PubMed ID: 34029766
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
6. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
7. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
8. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
9. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
10. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
13. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
[TBL] [Abstract][Full Text] [Related]
14. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
15. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch.
Al Malki MM; Gendzekhadze K; Yang D; Mokhtari S; Parker P; Karanes C; Palmer J; Snyder D; Forman SJ; Nademanee A; Nakamura R
Transplantation; 2020 May; 104(5):1070-1080. PubMed ID: 31449184
[TBL] [Abstract][Full Text] [Related]
16. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Joseph J; Srour SA; Milton DR; Ramdial JL; Saini NY; Olson AL; Bashir Q; Oran B; Alousi AM; Hosing C; Qazilbash MH; Kebriaei P; Shpall EJ; Champlin RE; Popat UR
Transplant Cell Ther; 2023 Dec; 29(12):770.e1-770.e6. PubMed ID: 37742746
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
18. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.
Bashir Q; Nishihori T; Pasquini MC; Martens MJ; Wu J; Alsina M; Anasetti C; Brunstein C; Dawson P; Efebera Y; Gasparetto C; Geller N; Giralt S; Hall AC; Koreth J; McCarthy P; Scott E; Stadtmauer EA; Vesole DH; Hari P
Transplant Cell Ther; 2023 Jun; 29(6):358.e1-358.e7. PubMed ID: 35840087
[TBL] [Abstract][Full Text] [Related]
20. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
